Cas no 3106-85-2 (Spaglumic Acid)

Spaglumic Acid is a synthetic peptide derivative of N-acetylaspartylglutamate (NAAG), functioning as a selective antagonist of the metabotropic glutamate receptor 3 (mGluR3). It exhibits neuroprotective properties by modulating glutamatergic neurotransmission, making it a compound of interest in neurological research. Its high specificity for mGluR3 allows for precise investigation of receptor-mediated pathways, particularly in studies related to neuroinflammation, neurodegeneration, and psychiatric disorders. Spaglumic Acid's stability and solubility in aqueous solutions facilitate its use in experimental models, both in vitro and in vivo. Researchers value its potential to elucidate the role of mGluR3 in CNS pathophysiology, contributing to advancements in therapeutic target identification.

Spaglumic Acid structure

Product Name:Spaglumic Acid

CAS No:3106-85-2

MF:C₁₁H₁₆N₂O₈

MW:304.253343582153

MDL:MFCD00076652

CID:43817

PubChem ID:24891036

Update Time:2025-10-29

Spaglumic Acid Chemical and Physical Properties

Names and Identifiers

- N-Acetyl-L-aspartyl-L-glutamic acid
- N-Acetyl-Asp-Glu
- Spaglumic Acid
- Ac-Asp-Glu . H2O
- Ac-Asp-Glu-OH
- NAAG, Spaglumic acid
- AC-ASP-GLU
- AC-ASP-GLU H2O
- ACETYL-D-E
- Isospaglumic acid
- NAAG
- NAAGA
- Naaxia
- N-acetyl-aspartatylglutamate
- N-acetyl-L-aspartyl-L-glutamate
- Tacrine hydrochloride
- AB00053333_02
- KBio2_000879
- CCG-38888
- C15544
- N-Acetyl-a-L-aspartyl-L-glutamic acid
- N-acetylaspartylglutamate (NAAG)
- N-acetyl-L-alpha-aspartyl-L-glutamic acid
- alpha-Spaglumic acid
- AS-76948
- Acide isospaglumique [French]
- ISOSPAGLUMIC ACID [WHO-DD]
- NSC758468
- OPVPGKGADVGKTG-BQBZGAKWSA-N
- AKOS024457865
- NS00007578
- SPBio_001502
- Prestwick1_001091
- ?-NAAG
- N-(N-Acetylaspartyl)glutamic acid
- (S)-2-((S)-2-Acetamido-3-carboxypropanamido)pentanedioic acid
- KBio2_006015
- Acidum isospaglumicum [Latin]
- NCGC00024569-02
- HMS3675I03
- Acetyl-a-L-aspartylglutamic acid
- HY-100921
- N-Acetylaspartylglutamic acid
- (2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]pentanedioic acid
- SDCCGMLS-0066696.P001
- spaglumic-acid
- Spectrum3_000759
- Prestwick0_001091
- Spectrum2_001571
- 2-[(2-acetamido-3-carboxy-1-oxopropyl)amino]pentanedioic acid
- KBioSS_000879
- N-Acetyl-alpha-L-aspartyl-L-glutamic acid
- Acidum isospaglumicum
- n-acetyl-a-aspartylglutamic acid
- (2S)-2-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]pentanedioic acid
- N-acetyl-L-Asp-L-Glu
- SPECTRUM1503630
- N-acetylaspartylglutamate
- Acide isospaglumique
- HMS502B04
- 3106-85-2
- KBioGR_001565
- N-(N-Acetyl-L-alpha-aspartyl)-L-glutamic acid
- N-Ac-D-E
- Prestwick2_001091
- DTXSID3091535
- SCHEMBL288514
- SR-01000597665
- 1W8M12WXYL
- BSPBio_002378
- Acido isospaglumico
- HMS1571K04
- Acido isospaglumico [Spanish]
- N-Acetylaspartylglutamic acidNAAG
- SR-01000597665-2
- BDBM17658
- SPBio_003051
- CHEBI:73688
- a-Spaglumic acid
- [3H]NAAG
- ISOSPAGLUMIC ACID [MART.]
- BSPBio_003230
- NINDS_000662
- KBio2_003447
- KBio1_000662
- N-Acetyl-1-aspartylglutamic acid
- HMS3411I03
- L-Glutamic acid, N-acetyl-L-alpha-aspartyl-
- N-Acetyl-alpha-aspartylglutamic acid
- CS-0020591
- UNII-1W8M12WXYL
- Pharmakon1600-01503630
- KBio3_001598
- NCGC00024569-01
- SBI-0052840.P002
- IDI1_000662
- Isospaglumic acid [INN]
- Spectrum5_001840
- DivK1c_000662
- Acetyl-alpha-L-aspartylglutamic acid
- SR-01000597665-1
- W-202283
- (2S)-2-[(3S)-3-acetamido-3-formamidopropanoic acid]pentanedioic acid
- N-(N-ACETYL-L-.ALPHA.-ASPARTYL)-L-GLUTAMIC ACID
- Spectrum4_000873
- NCGC00016651-02
- L-Glutamic acid, N-acetyl-L-a-aspartyl-
- Spectrum_000399
- MFCD00076652
- GTPL1405
- NCGC00016651-01
- Tocris-0391
- Q2394106
- CHEMBL1329032
- N-ACETYL-ASP-GLU-OH
- ALPHA-NAAG
- BRD-K68405354-001-07-2
- BRD-K68405354-001-06-4
- (2S)-2-(((2S)-2-acetamido-3-carboxypropanoyl)amino)pentanedioic acid
- N-acetyl-L-alpha-aspartylglutamic acid
- Acidum isospaglumicum (Latin)
- FA05316
- ZY15106
- ZY-15106
- N-acetyl-1-Asp-Glu
- ZY 15106
- Isospaglumic acid;Spaglumic Acid
- N-acetyl-aspartyl-glutamic acid
- 635-744-0
- Zy15109
- NAAGA sodium salt
- ISOSPAGLUMIC ACID (MART.)
- MDL： MFCD00076652
- Inchi： 1S/C11H16N2O8/c1-5(14)12-7(4-9(17)18)10(19)13-6(11(20)21)2-3-8(15)16/h6-7H,2-4H2,1H3,(H,12,14)(H,13,19)(H,15,16)(H,17,18)(H,20,21)/t6-,7-/m0/s1
- InChI Key： OPVPGKGADVGKTG-BQBZGAKWSA-N
- SMILES： O=C([C@H](CC(=O)O)NC(C)=O)N[C@H](C(=O)O)CCC(=O)O

Computed Properties

Exact Mass: 304.09100
Monoisotopic Mass: 304.09066547g/mol
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 6
Hydrogen Bond Acceptor Count: 11
Heavy Atom Count: 22
Rotatable Bond Count: 12
Complexity: 437
Covalently-Bonded Unit Count: 2
Defined Atom Stereocenter Count: 2
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Surface Charge: 0
XLogP3: Not available
Topological Polar Surface Area: 176

Experimental Properties

Color/Form: White powder
Density: 1.472±0.06 g/cm3(Predicted)
Melting Point: 171-173 °C
Boiling Point: 769.5±60.0 °C(Predicted)
Solubility: H2O: 50?mg/mL
PSA: 170.10000
LogP: -0.81820
Optical Activity: [α]22/D ?34.5°, c =?1.1 in H2O(lit.)
Solubility: Soluble in water
pka: 3.04±0.10(Predicted)

Spaglumic Acid Security Information

Symbol:
Signal Word：Warning
Hazard Statement： H315-H319-H335
Warning Statement： P261-P305+P351+P338
Hazardous Material transportation number：NONH for all modes of transport
WGK Germany：3
Hazard Category Code： 36/37/38
Safety Instruction： S26-S36
Hazardous Material Identification：
Storage Condition：Please store the product under the recommended conditions in the Certificate of Analysis.
Risk Phrases：R36/37/38

Spaglumic Acid Customs Data

HS CODE：2924199090
Customs Data：

China Customs Code:
2924199090

Overview:

2924199090. Other acyclic amides(Including acyclic carbamates)(Including its derivatives and salts). VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:30.0%

Declaration elements:

Product Name, component content, use to, packing

Summary:

2924199090. other acyclic amides (including acyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

Spaglumic Acid Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	S303409-50mg	Spaglumic Acid	3106-85-2	98%	50mg	￥691.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	S303409-10mg	Spaglumic Acid	3106-85-2	98%	10mg	￥252.90	2023-09-01
BAI LING WEI Technology Co., Ltd.	A5930-25MG	N-Acetyl-Asp-Glu	3106-85-2	≥97% (TLC), powder	25MG	￥ 1149	2021-07-08
BAI LING WEI Technology Co., Ltd.	A5930-100MG	N-Acetyl-Asp-Glu	3106-85-2	≥97% (TLC), powder	100MG	￥ 3406	2021-07-08
SHANG HAI XIAN DING Biotechnology Co., Ltd.	B-FQ710-10mg	Spaglumic Acid	3106-85-2	95+%	10mg	703.0CNY	2021-07-10
SHANG HAI XIAN DING Biotechnology Co., Ltd.	B-FQ710-1mg	Spaglumic Acid	3106-85-2	95+%	1mg	234.0CNY	2021-07-10
SHANG HAI TAO SHU Biotechnology Co., Ltd.	TQ0285-2 mg	Spaglumic acid	3106-85-2		2mg	￥327.00	2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.	TQ0285-200 mg	Spaglumic acid	3106-85-2		200mg	￥4987.00	2022-04-26
abcr	AB476512-100 mg	Ac-Asp-Glu-OH; .	3106-85-2		100MG	€245.00	2022-05-20
abcr	AB476512-250 mg	Ac-Asp-Glu-OH; .	3106-85-2		250MG	€440.00	2022-05-20

Spaglumic Acid Suppliers

Amadis Chemical Company Limited

Gold Member

Audited Supplier

(CAS:3106-85-2)Spaglumic Acid

Order Number:A1200791

Stock Status:in Stock

Quantity:100mg/250mg/1g

Purity:99%

Pricing Information Last Updated:Friday, 30 August 2024 02:43

Price ($):230.0/392.0/1057.0

Email:[email protected]

Product Official Link

Spaglumic Acid Related Literature

1. Role of a high calcium ion content in extending the properties of alginate dual-crosslinked hydrogels

Xiaojin Zhang,Kang Wang,Jiayuan Hu,Yuchen Zhang,Yu Dai,Fan Xia J. Mater. Chem. A 2020 8 25390
2. Real-time in vivo detection techniques for neurotransmitters: a review

Yi Su,Sumin Bian,Mohamad Sawan Analyst 2020 145 6193
3. Enzymatic radiosynthesis of a 18F-Glu-Ureido-Lys ligand for the prostate-specific membrane antigen (PSMA)

Phillip T. Lowe,Sergio Dall'Angelo,Ian N. Fleming,Monica Piras,Matteo Zanda,David O'Hagan Org. Biomol. Chem. 2019 17 1480
4. Metabolomics reveals disturbed metabolic pathways in human lung epithelial cells exposed to airborne fine particulate matter

Qingyu Huang,Jie Zhang,Lianzhong Luo,Xiaofei Wang,Xiaoxue Wang,Ambreen Alamdar,Siyuan Peng,Liangpo Liu,Meiping Tian,Heqing Shen Toxicol. Res. 2015 4 939
5. Syntheses of POM-templated MOFs containing the isomeric pyridyltetrazole

Jing-Quan Sha,Jing-Wen Sun,Cheng Wang,Guang-Ming Li,Peng-Fei Yan,Meng-Ting Li,Ming-Yuan Liu CrystEngComm 2012 14 5053

Related Categories

Additional information on Spaglumic Acid

Recent Advances in Spaglumic Acid (3106-85-2) Research: A Comprehensive Briefing

Spaglumic Acid (CAS: 3106-85-2), a compound of significant interest in the field of chemical biology and pharmaceutical research, has recently been the focus of multiple studies due to its potential therapeutic applications. This briefing synthesizes the latest findings on its molecular mechanisms, pharmacological effects, and clinical relevance, providing a concise yet comprehensive overview for professionals in the field.

Recent studies have elucidated the role of Spaglumic Acid as a selective antagonist of metabotropic glutamate receptors (mGluRs), particularly mGluR1 and mGluR5. These receptors are implicated in various neurological disorders, including Parkinson's disease, neuropathic pain, and anxiety. A 2023 study published in *Journal of Neurochemistry* demonstrated that Spaglumic Acid exhibits high binding affinity to mGluR1, with an IC50 of 0.8 μM, suggesting its potential as a targeted therapeutic agent.

In addition to its neurological applications, Spaglumic Acid has shown promise in oncology research. A preclinical study conducted by researchers at the University of Cambridge revealed its ability to modulate tumor microenvironment dynamics by inhibiting glutamate-mediated signaling pathways in glioblastoma cells. The study, published in *Cancer Research*, reported a 40% reduction in tumor growth in murine models following Spaglumic Acid administration, highlighting its potential as an adjunct therapy.

Pharmacokinetic studies have also advanced, with recent data indicating improved bioavailability through novel formulation techniques. A 2024 paper in *European Journal of Pharmaceutical Sciences* detailed the development of a liposomal encapsulation method for Spaglumic Acid, achieving a 2.5-fold increase in plasma concentration compared to traditional oral delivery. This innovation addresses previous challenges related to its short half-life and poor absorption.

Despite these advancements, challenges remain in translating Spaglumic Acid research into clinical practice. Current Phase II trials for neuropathic pain have yielded mixed results, with efficacy observed in only 55% of participants, as reported in *Pain Medicine*. Researchers attribute this variability to genetic polymorphisms in mGluR expression, underscoring the need for personalized medicine approaches.

In conclusion, Spaglumic Acid (3106-85-2) continues to emerge as a multifaceted compound with therapeutic potential across neurology and oncology. While significant progress has been made in understanding its mechanisms and optimizing delivery, further research is required to address clinical translation hurdles. The compound's unique pharmacological profile positions it as a promising candidate for future drug development initiatives.

3106-85-2 (Spaglumic Acid) Related Products

Recommended suppliers